$1 Million State Investment Advances HIV Cure Research at the Miller School
A $1 million state investment will help the Miller School’s HEIDI Institute support early-stage studies, build evidence for federal grants and advance potential HIV cure strategies.
The University of Miami Miller School of Medicine’s HIV/AIDS and Emerging Infectious Diseases Institute (HEIDI) received a $1 million state donation championed by Florida Sen. Ana Maria Rodriguez and Rep. Dana Trabulsy during a presentation ceremony held Friday, Aug. 28, at the HEIDI laboratory, located in Converge Miami, just blocks from the Miller School campus.
The funding reflects continued community and state support for the institute’s mission to prevent, treat and ultimately cure HIV.
“It is truly an honor to sponsor this legislative funding request year after year because of the profound impact it has on people living with HIV,” Rodriguez said. “This investment brings hope to our state and to communities around the world as researchers continue working toward a cure for this devastating disease.”
“I’m incredibly grateful to have secured funding for HIV/AIDS research at the HEIDI Institute. I’ve been fortunate to have a wonderful Senate sponsor and to work alongside dedicated researchers and advocates who are doing truly incredible work,” added Rep. Trabulsy. “Supporting this life-saving research is something I’m deeply committed to because the work being done today has the potential to change and save lives for generations to come.”
Key Takeaways
- A $1 million state investment will support HIV cure research at the Miller School’s HEIDI Institute.
- Pilot funding helps investigators generate preliminary data needed to pursue larger federal grants.
- One supported project is advancing an antibody-based HIV research strategy toward clinical evaluation.
How Will the Funds Support HIV Cure Research?
The state investment will advance HIV cure research while providing pilot funding that helps Miller School investigators generate the preliminary data needed to compete successfully for federal grants.
Mario Stevenson, Ph.D., director of HEIDI and professor in the Miller School’s Division of Infectious Diseases, said the funding is essential to moving promising ideas from the laboratory toward real-world solutions.
“We hope to identify a simple and scalable cure for HIV,” Dr. Stevenson said. “If successful, this would have a tremendous impact on Florida residents, given that the state continues to face one of the nation’s highest HIV burdens. The impact on health outcomes, costs, stigma and HIV-related diseases would be immense.”
Driving Innovation Through Pilot Research
Founded in 2015, HEIDI was created to foster cross-disciplinary collaboration in HIV prevention, treatment and cure research while advancing a zero-transmission future.
A cornerstone of the institute’s work is supporting high-risk, high-reward pilot projects that position university researchers to attract larger federal grants and accelerate scientific discovery.
One such project is led by Ronald Desrosiers, Ph.D., professor of pathology and laboratory medicine at the Miller School. His team is developing a strategy that turns muscle cells into antibody-producing factories capable of eliminating HIV.
The research has advanced to the point where investigators are preparing to evaluate the approach in a clinical trial.
“The research leading to this advancement would not have been possible without state funding,” Dr. Stevenson said.
Why This Research Matters
Current HIV treatments can control the virus, but Miller School investigators continue to pursue research strategies aimed at an HIV cure.
The state funding gives investigators pilot support to test promising ideas and generate the preliminary data needed to compete for larger federal grants.
Over time, this work could help researchers evaluate approaches designed to be simpler and more scalable, while important scientific and clinical questions remain under study.
A Path Toward a Cure
HEIDI-funded pilot awards support exploratory projects that often struggle to secure traditional funding during their earliest stages. Yet those projects have already contributed meaningful advances in HIV cure research.
With this latest $1 million investment, HEIDI researchers will continue pursuing potential cure pathways that could ultimately benefit the nearly 40 million people living with HIV worldwide.
The funding also expands the capacity of the University of Miami Center for AIDS Research (CFAR), which coordinates HIV/AIDS research across the university. HEIDI serves as the university’s dedicated HIV cure research arm.
To learn more about HEIDI, email Narina Janian or call (305) 302-8755.
More from the Miller School of Medicine
Dr. Ronald Desrosiers’ HIV research at the University of Miami explores gene therapy and broadly neutralizing antibodies.
University of Miami’s CFAR symposium showcased advances in HIV treatment, cure research and implementation science.
The clinic’s implementation reflects UHealth’s dedication to its mission to bring high‑quality specialty care directly into the community.
The Miller School institute marked 10 years of research progress and outlined future steps toward an HIV/AIDS cure.
Tags: AIDS, CFAR, Division of Infectious Diseases, Dr. Mario Stevenson, Dr. Ronald Desrosiers, Dr. Sebastian Fuchs, HEIDI, HIV, HIV/AIDS, Infectious diseases, Miami Center for AIDS Research